PITTSBURGH, Dec. 13 /PRNewswire/ -- The Pittsburgh Life Sciences Greenhouse (PLSG), the organization providing capital investments and customized company formation and business growth services to the region's life sciences enterprises, announced that the PLSG has invested $100,000 in ParentPlus. ParentPlus was formed to commercialize innovative and proprietary human fertility technologies and provide subfertile couples worldwide better odds of fulfilling their dream to start a family. Subfertility affects couples, not individuals, and 75 million couples are impacted world-wide. Of these, only 56% seek treatment and a mere 22 % get treatment.
ParentPlus is positioning its initial product, FertPlus(R), to increase the efficacy of fertility treatments and at the same time provide a lower cost alternative to expensive and highly publicized conventional treatments.
The PLSG's $100,000 investment will help ParentPlus develop FertPlus(R) and conduct a sufficiently-sized medical school study to compare binding of sperm exposed to hPSF with a control. The resulting data will be used to prepare for a pre-trial conference with the Food and Drug Administration (FDA) to obtain clearance to market. After clearance by the FDA, FPSPM can be introduced to fertility clinics as the medium used in sperm preparation for IntraUterine Insemination (IUI) treatment.
"Currently there is no other treatment available to enhance the success of IUI," said John W. Manzetti, President & CEO of the PLSG. "The ParentPlus technology will provide couples with a reduced number of insemination attempts, which helps alleviate the financial and emotional stress associated with subfertility." Mr. Manzetti continued, "There are currently no FDA- approved pro-fertility products acting on human sperm. The development and success of ParentPlus' product will be the first such medium with significant potential to increase the probability of couples becoming pregnant and can ultimately impact the success of fertility clinics worldwide. "
About the Pittsburgh Life Sciences Greenhouse (PLSG)
The PLSG invests in and supports the growth of biosciences companies in southwestern Pennsylvania. The PLSG has investment and business growth programs to increase the linkage between research, technology and commercialization; nurture and develop entrepreneurial biosciences enterprises; grow the region's talent pool in the life sciences; and help biosciences firms locate, expand or start-up in the Greater Pittsburgh region. http://www.plsg.com
ParentPlus LLC was formed to alleviate male-factor subfertility by bringing innovative biotechnology to millions of subfertile couples for whom intra-uterine insemination (IUI) might be an appropriate therapy. This therapy, with spousal or donor sperm, is underutilized . perhaps in part because it is not typically discussed in the popular press.
It is ParentPlus' belief that sperm from many subfertile men should be the target of a therapy based on modern biotechnology. Successful application of this concept could allow far more subfertile couples, when male-factor subfertility is a problem, to use IUI with spousal sperm to fulfill their dream of a having a baby. Hence, the focus of ParentPlus LLC is on innovative reproductive media to enhance success primarily via IUI, but also enhancing IVF. In due course, demonstrated increased "success rate" with IUI using ParentPlus products will increase acceptance of IUI as the low cost alternative to highly publicized expensive treatments. http://www.parentplus.net
|SOURCE Pittsburgh Life Sciences Greenhouse|
Copyright©2007 PR Newswire.
All rights reserved